Editorial

A Milestone in Diabetes: CRISPR-Modified Cells Achieve Immune Escape

The clinical translation of gene-edited cellular therapies has hit a new milestone with the recent demonstration of CRISPR-engineered pancreatic islet cells functioning to produce insulin while evading immune destruction in a patient afflicted with type 1 diabetes mellitus (T1DM). The ground-breaking study, therefore, becomes a landmark in cell replacement therapy, as one of the major hurdles in the way had been the need to put the patient on lifelong immunosuppression. In a 42-year-old long-standing T1DM patient, pancreatic islet cells allogeneically HLA-type-mismatched were implanted following CRISPR-Cas9-mediated gene editing ex vivo to induce a hypoimmune phenotype. This was done by ablating genes encoding for human leukocyte antigen (HLA) class I and II molecules, thus eliminating the main targets of T cell-mediated alloimmunity. To further protect the graft from destruction, the cells were engineered to overexpress CD47, a "don't-eat-me" signal that blocks innate immune clearance by macrophages and natural killer (NK) cells. The cells were engrafted into the forearm muscle site, vascularized yet surgically accessible. During a 12-week follow-up, the engineered cells did not require the use of immunosuppression drugs, produced insulin in a glucose-responsive fashion, and participated in postprandial glycemic control. Despite the graft comprising a small fraction, ~7%, of a complete functional islet mass, thus requiring ongoing exogenous insulin therapy, the outcome constitutes strong evidence of principle. The therapeutic potential of islet transplantation has been historically limited by two obstacles: a lack of available donor tissue and the side effect burden of systemic immunosuppression. The present study directly overcomes the latter hurdle. By providing evidence of durable immune avoidance in a human recipient, the field has a distinct clinical analogue that proves engineered immune cloaking is possible. Notably, the study arrives at a point at which a number of groups are bringing pluripotent stem cell–derived β-like cells to the point of usable therapy. If hypoimmune engineering were to be synergized with stem cell–driven differentiation protocols, it would provide a renewable and reproducible source of immune-protected insulin-secreting tissue. It has the promise to redefine therapy for T1DM by facilitating functional cure rather than longitudinal management.

Recent Developments

It is important to consider this milestone in the context of immunoengineering and regenerative medicine. To ensure reproducibility and safety for clinical use, researchers have recently reported progress in scaling up the manufacturing of stem cell-derived islets under GMP conditions. Numerous biotech firms are currently investigating CRISPR-based immune cloaking in hepatocytes, cardiomyocytes, and islets, indicating a broader range of applications for the strategy. By employing partial graft doses in a monitored environment, the September 2025 trial notably addressed a major safety concern and demonstrated insulin production without subjecting the patient to the dangers of a full-scale transplant. The forearm muscle was selected as the implantation site because it provided convenient access for monitoring, biopsy, and possible removal in the event of unfavorable outcomes. A cautious and translationally sound approach to early-phase testing is reflected in this surgical strategy. Before being implanted, the modified cells underwent stringent quality control procedures, such as sterility tests to satisfy regulatory requirements and genomic integrity checks to make sure there were no off-target CRISPR alterations. As gene editing pipelines advance from experimental models to human applications, these precautions demonstrate their growing maturity.

A number of disclaimers temper the excitement despite the promise. First, the clinical trial is still in its early stages, with only one patient reported and a short follow-up period. Larger patient cohorts from multicenter studies will be required to prove generalizability and reproducibility. Second, there was no attainment of insulin independence. The graft size was small, and it is unknown if scaled grafts can maintain complete insulin production without inducing breakthrough immunity. Careful research is needed to determine the hypoimmune cells' long-term viability and functional integration into systemic glucose regulation. Third, safety concerns are also raised by HLA deletion, the very trait that provides immune invisibility. Immune

surveillance systems that typically prevent malignant transformation may be circumvented by cells devoid of HLA. Therefore, extra safety layers that could be triggered in the event of aberrant cell proliferation, like inducible suicide switches, are being considered by researchers and regulators. Lastly, the short-term issue of donor scarcity has not been addressed. Due to the limited number of allogeneic islets, integration with stem cell technologies will be necessary for large-scale therapeutic applications to provide an infinite source of cells. Hypoimmune engineering may be used in conjunction with induced pluripotent stem cell-derived β-like cells, according to recent reports, although these approaches are still being developed.

Conclusion

More than a small step forward, the first report of immune-evasive, CRISPR-modified islet cells surviving and functioning in a human without immunosuppression represents a clinical milestone. It supports decades of theoretical work in regenerative medicine and immune cloaking. Although there are still obstacles to overcome, the accomplishment offers a solid basis for the long-term objective of a functional cure for type 1 diabetes. It marks a change for patients from using insulin injections to treat their diabetes to the potential for living tissue-based treatments. For the discipline, it signals a more expansive era where immune-evasive, gene-edited cells could revolutionize regenerative medicine and transplantation.

References

Karaoglu, I. C., Duymaz, D., Rashid, M. M., & Kizilel, S. (2025). Immune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling. Frontiers in immunology, 16, 1618086. https://doi.org/10.3389/fimmu.2025.1618086

Harding, J., Vintersten-Nagy, K., Yang, H., Tang, J. K., Shutova, M., Jong, E. D., Lee, J. H., Massumi, M., Oussenko, T., Izadifar, Z., Zhang, P., Rogers, I. M., Wheeler, M. B., Lye, S. J., Sung, H. K., Li, C., Izadifar, M., & Nagy, A. (2024). Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts. Nature biomedical engineering, 8(4), 427-442. https://doi.org/10.1038/s41551-023-01133-y

https://www.wired.com/story/no-more-injections-crispr-offers-new-hope-for-treating-diabetes/

https://www.livescience.com/health/diabetes/diabetic-man-produces-his-own-insulin-after-gene-edited-cell-transplant

Hoang, V. T., Nguyen, Q. T., Phan, T. T. K., Pham, T. H., Dinh, N. T. H., Anh, L. P. H., Dao, L. T. M., Bui, V. D., Dao, H. N., Le, D. S., Ngo, A. T. L., Le, Q. D., & Nguyen Thanh, L. (2025). Tissue Engineering and Regenerative Medicine: Perspectives and Challenges. MedComm, 6(5), e70192. https://doi.org/10.1002/mco2.70192

Cetin, B., Erendor, F., Eksi, Y. E., Sanlioglu, A. D., & Sanlioglu, S. (2025). Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert reviews in molecular medicine, 27, e16. https://doi.org/10.1017/erm.2025.10

Wang, X., Zeng, Z., Li, D., Wang, K., Zhang, W., Yu, Y., & Wang, X. (2025). Advancements and Challenges in Immune Protection Strategies for Islet Transplantation. Journal of diabetes, 17(1), e70048. https://doi.org/10.1111/1753-0407.70048

Karaoglu, I. C., Duymaz, D., Rashid, M. M., & Kizilel, S. (2025). Immune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling. Frontiers in immunology, 16, 1618086. https://doi.org/10.3389/fimmu.2025.1618086

Bertrand, O. F. (2010). Acute forearm muscle swelling post transradial catheterization and compartment syndrome: prevention is better than treatment!. Catheterization and Cardiovascular Interventions, 75(3), 366-368.

Tahbaz, M., & Yoshihara, E. (2021). Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes. Frontiers in endocrinology, 12, 716625. https://doi.org/10.3389/fendo.2021.716625

Dr Puja Gulati
Professor and Principal
School of Pharmacy
Desh Bhagat University